Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling? (vol 26, pg 211, 2023)

被引：0
|
作者：
Chen, Ethan
Ling, Alexander L.
Reardon, David A.
Chiocca, E. Antonio
机构：
来源：
NEURO-ONCOLOGY | 2024年 / 26卷 / 04期
关键词：
D O I：
10.1093/neuonc/noad241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：779 / 779
页数：1
相关论文
共 50 条
  • [41] Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study (vol 16, pg 793, 2023)
    Sidonio, R. F.
    Thompson, A. A.
    Peyvandi, F.
    Stasyshyn, O.
    Yeoh, S. L.
    Sosothikul, D.
    Antmen, A. B.
    Maggiore, C.
    Engl, W.
    Ewenstein, B.
    Tangada, S.
    EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (1-3) : 101 - 101
  • [42] Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies (vol 53, pg 687, 2023)
    Nester, Carla
    Appel, Gerald B.
    Bomback, Andrew S.
    Bouman, Koenraad Peter
    Cook, H. Terence
    Daina, Erica
    Dixon, Bradley P.
    Rice, Kara
    Najafian, Nader
    Hui, James
    Podos, Steven D.
    Langman, Craig B.
    Lightstone, Liz
    Parikh, Samir, V
    Pickering, Matthew C.
    Sperati, C. John
    Trachtman, Howard
    Tumlin, James
    de Vries, Aiko P. J.
    Wetzels, Jack F. M.
    Remuzzi, Giuseppe
    AMERICAN JOURNAL OF NEPHROLOGY, 2023,
  • [43] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials (vol 14, pg 2235, 2024)
    Armstrong, April W.
    Augustin, Matthias
    Beaumont, Jennifer L.
    Pham, Tan P.
    Hudgens, Stacie
    Gordon, Kenneth B.
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Kisa, Renata M.
    Banerjee, Subhashis
    Papp, Kim A.
    DERMATOLOGY AND THERAPY, 2025, : 1037 - 1044
  • [44] Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (21) : 3767 - 3767
  • [45] Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma ( CLEAR): extended followup from the phase 3, randomised, open-label study (vol 24, pg 228, 2023)
    Choueiri, T. K.
    Eto, M.
    Motzer, R.
    LANCET ONCOLOGY, 2023, 24 (04): : E146 - E146
  • [46] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 457 - 457
  • [47] Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib (vol 60, pg 188, 2020)
    Mohamed, Mohamed-Eslam F.
    Beck, Denise
    Voss, Jeffrey
    Camp, Heidi S.
    Othman, Ahmed A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (04): : 551 - 551
  • [48] Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials (vol 9, pg 527, 2023)
    Walls, Gerard M.
    Hanna, Gerard G.
    JAMA ONCOLOGY, 2023, 9 (04) : 574 - 574
  • [49] Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial (vol 67, pg 301, 2023)
    Mori, Ryusaburo
    Honda, Shigeru
    Gomi, Fumi
    Tsujikawa, Akitaka
    Koizumi, Hideki
    Ochi, Haruka
    Ohsawa, Shino
    Okada, Annabelle Ayame
    TENAYA and LUCERNE Investigators
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2023, 67 (03) : 311 - 311
  • [50] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial (vol 401, pg 105, 2023)
    Valderas, Jose M.
    Stavdal, Anna
    Hanson, Kara
    Teo, Yik Ying
    Chong, Yap Seng
    Wong, John E. L.
    Legido-Quigley, Helena
    LANCET, 2023, 401 (10376): : 556 - 556
12345